Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
mineralocorticoid synthetic corticosteroid |
| gptkbp:approvedBy |
gptkb:United_States
|
| gptkbp:ATCCode |
H02AA02
|
| gptkbp:brand |
Florinef
|
| gptkbp:CASNumber |
127-31-1
|
| gptkbp:category |
cardiology
endocrinology |
| gptkbp:chemicalClass |
gptkb:Corticosteroid
fluorinated steroid |
| gptkbp:contraindication |
systemic fungal infection
hypersensitivity to fludrocortisone |
| gptkbp:discoveredBy |
gptkb:Upjohn
|
| gptkbp:eliminationHalfLife |
18-36 hours
|
| gptkbp:excretion |
renal
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:hasMolecularFormula |
C21H29FO5
|
| https://www.w3.org/2000/01/rdf-schema#label |
fludrocortisone
|
| gptkbp:introducedIn |
1954
|
| gptkbp:IUPACName |
(8S,9R,10S,11S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
glucocorticoid receptor agonist (weak)
mineralocorticoid receptor agonist |
| gptkbp:meltingPoint |
265°C
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:origin |
synthetic derivative of cortisol
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescribes |
postural hypotension
adults with Addison's disease pediatric patients with congenital adrenal hyperplasia |
| gptkbp:proteinBinding |
70%
|
| gptkbp:PubChem_CID |
5865
5660 CHEMBL1200697 DB00687 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
heart failure
edema headache hypertension hypokalemia |
| gptkbp:solubility |
practically insoluble in water
|
| gptkbp:synonym |
9α-fluorocortisol
9α-fluoro-11β,17α,21-trihydroxypregn-4-ene-3,20-dione |
| gptkbp:UNII |
8VZV102JFY
|
| gptkbp:usedFor |
gptkb:orthostatic_hypotension
Addison's disease adrenal insufficiency salt-losing adrenogenital syndrome |
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:orthostatic_hypotension
gptkb:Corticosteroid |
| gptkbp:bfsLayer |
6
|